Ovagen HomeCompanyInvestorsContact
  Ovagen - The Company  
Ovagen   Ovagen
Ovagen Ovagen Ovagen Ovagen Ovagen


• The Ovagen team has a wealth of technical, operational, financial and management experience.  Our Research and Development team has 100 years of combined life-sciences related R&D experience. Our  previous venture was successfully sold in 2002 to Charles River Laboratories Inc.

• Ovagen is a biotechnology company that has developed a patented process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry for vaccine manufacture. The company can also offer large sale production of recombinant proteins to GMP standard using a transgenic chicken plaform,

• Ovagen has a custom antibody service, focussing on the production of high quality IgY antibodies. The company also specialises in avian transgenic technology and has a fully equipped transgenic laboratory.

• Ovagen has an extensive patent portfolio and strong IP for the process by which it produces GF eggs.

• The company has achieved proof of concept and produced germ free eggs from three generations of germ free birds. The company has built a state-of-the-art avian facility on its seven acre site which will be used to produce the initial flocks of germ free birds and germ free eggs for customer evaluation and viral yield analysis in Q3 2021. Plans are in place to build two additional germ free production facilities and a logistics building for which planning permission has been received. 

This will enable the production of 4 million germ free eggs

• To produce GF eggs on a large-scale, Ovagen will use sterile manufacturing technologies as developed in the pharmaceutical industry in conjunction with biosafety decontamination techniques and best-practice poultry husbandry methods.

• Sectors Targetted: Pharmaceutical, Biopharma, Diagnostic, Research Institutes






Dr. Catherine Caulfield (B.Sc., Ph.D., HDE, MBA, C.Biol., F.I.Biol)
Founder & Chief Executive Officer
Catherine is responsible for spearheading the operational development of the business at Ovagen. Her business acumen has guided the company through its earlier research stages and now plays a key role in commercialization. Catherine, with Leonard Moran, was the co-founder of Biological-Laboratories Europe Limited (BioLabs). In BioLabs Europe with a team of enthusiastic, committed and professional staff, Catherine spearheaded the development of the company. She held management positions ranging from Quality Manager to CEO, a position she enjoyed for 14 years. As CEO, BioLabs revenue increased by over 800% and when the company was sold in 2002, Catherine was pivotal in the successful integration of the new structure, having responsibility for the strategic, financial and operational leadership of the business. Dr. Caulfield has held many Board Memberships including the West Regional Board of Enterprise Ireland, The Irish National Accreditation Board (INAB), The National Standards Authority of Ireland (NSAI), and The Irish Council for Science Technology and Innovation (ICSTI). In 2009, she was appointed to the Governing Authority of the National University of Ireland, Galway and was a recipient of NUI Galway's prestigious Alumni Award for Natural Science, acknowledging her demonstrated excellence in the field of natural science industries.

Leonard Moran (Dip. Ag. Sci., F.I.Biol., F.I.A.T., A.I.S.T.).
Chairman & Chief Technical Officer
Leonard has led the business since inception and was the primary driver of the development of the Ovagen process to produce GF eggs. Prior to establishing Ovagen, Leonard founded Biological Laboratories Europe Limited (Biolabs). Leonard has amassed a wide range of GF technology skills and these have enabled him with the others in the management team to perfect the Ovagen process. Prior to founding Biolabs, Leonard spent 8 years with the British Medical Research Council (MRC) from 1968-76 where he focused on clinical research and specifically breeding SPF animals. In addition he has a wealth of practical operational and construction experience associated with biological facilities.

Dr. Martin Murphy (MVB MAnSc PhD MRCVS FCMI CMgr)
Senior Project Director
As Senior Project Director Martin is responsible for project management, oversight & co-ordination activities, milestone achievements, regulatory compliance, operational planning, risk mitigation and project execution. Martin previously worked as Director of Global Operations for Elanco Animal Health, Switzerland and Head of Global drug efficacy at Novartis, Switzerland and was Director of Veterinary Product Development at Charles river Laboratories. Martin received his PhD in Veterinary medicine from University College Dublin

Dr. Iain Shaw (B.Sc., Ph.D.)
Senior Scientist
Iain Shaw is a Senior Research Fellow and received his PhD in Veterinary Medicine from the Royal Veterinary College/Institute for Animal Health Compton. His research focussed on the development of recombinant subunit vaccines to viral diseases of chickens and understanding the molecular mechanisms of their action. Iain subsequently joined National University of Ireland Galway as a Senior Scientist further developing the technologies surrounding peptide based vaccination startegies for agricultural species. During this time Iain also led research projects producing recombinant antibody fragments in chickens for use in the diagnostic field. Iain joined Ovagen in 2009 initially to carry out research for an EU funded programme developing transgenic technologies for the large sclae production of recombinaint antibodies in chickens for the use in purification of stem cells from human bone marrow. Iain has also been the lead Ovagen scientist on collaborative projects with the Roslin Institute, University of Edinburgh, working closely with Professor Helen Sang to develop the transgenic technology for the production of whole recombinant antibodies for use in cancer therapies. Iain also provides the scientific lead in the Ovagen antibody contract production service.

Oliver Timlin
Financial Controller
At Ovagen, Oliver is responsible for all financial controls, treasury, tax compliance, planning and cost management.




Facilities (2500msq)

    First generation germ-free flocks

    • Avian Isolators, Incubators
    • Laboratories (Microbiology and Transgenic)
    • R&D
    • Head Office

    Lower Floor Provides:

    • SPF flocks
    • Large Germ-Free (GF) production isolators
    • GF suite for flock of 1000 birds
    • GF feed handling
    • GF egg collection & packaging

    Upper Floor Provides:

    • SPF showers
    • Incubating/Hatching Isolators
    • Transport Isolators
    • Laboratories & QA
    • Head Offices
    • Site BMS & IT facilities

Ovagen Ovagen Ovagen Ovagen Ovagen
Ovagen   Ovagen
Ovagen Ovagen